aTYR PHARMA INC
ATYR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001339970
No open-market purchases or sales by aTYR PHARMA INC insiders were filed in the last 90 days; 89 institutions reported holding it in 13F filings for Q2 2026, worth $23.2M in total; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding aTYR PHARMA INC changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Q4 2022 | Change |
|---|---|---|---|
| Holders | 33 | 36 | +3 |
| Shares | 19.1M | 18.4M | −706.5K (−3.7%) |
| Value | $57.2M | $40.2M | −$17.0M (−29.7%) |
New holders (8)
Institutions that held aTYR PHARMA INC at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citigroup Inc | 428,460 | $938.3K | 0.00% |
| Millennium Management LLC | 68,106 | $149.0K | 0.00% |
| Citadel Advisors LLC | 37,837 | $82.9K | 0.00% |
| Acadian Asset Management LLC | 26,419 | $57.0K | 0.00% |
| Wolverine Trading, LLC | 22,685 | $50.0K | 0.00% |
| Simplex Trading, LLC | 12,214 | $26.0K | 0.00% |
| JPMorgan Chase & Co | 2,597 | $6.00K | 0.00% |
| Bank of America Corp | 64 | $140 | 0.00% |
Sold out (5)
Institutions that held aTYR PHARMA INC at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Stonepine Capital Management, LLC | 600,980 | $1.80M |
| Susquehanna International Group, LLP | 45,542 | $137.0K |
| Group One Trading, L.P. | 14,461 | $43.0K |
| UBS Group AG | 5,975 | $18.0K |
| BNP Paribas Arbitrage, SA | 1,784 | $5.35K |